MedTrace Logo

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine if stopping the stress induced increase in inflammation will prevent sodium retention which in turn increases blood pressure. Each subject will test two separate times. One week, they will be taking a daily dose of mycophenolate mofetil (MMF), the other week they will be taking a placebo.

Conditions

  • Psychological Stress
  • Hypertension, Renal

Interventions

DRUG

mycophenolate mofetil (MMF)

an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form

DRUG

Placebo

a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF

Sponsors & Collaborators

  • Augusta University

    lead OTHER

Principal Investigators

  • Gregory A Harshfield, PhD · Augusta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-22
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432339 on ClinicalTrials.gov